{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:34:36Z","timestamp":1778945676346,"version":"3.51.4"},"reference-count":66,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>To review recent lecithin:cholesterol acyltransferas (LCAT)-based therapeutic approaches for atherosclerosis, acute coronary syndrome, and LCAT deficiency disorders.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>A wide variety of approaches to using LCAT as a novel therapeutic target have been proposed. Enzyme replacement therapy with recombinant human LCAT is the most clinically advanced therapy for atherosclerosis and familial LCAT deficiency (FLD), with Phase I and Phase 2A clinical trials recently completed. Liver-directed <jats:italic toggle=\"yes\">LCAT<\/jats:italic> gene therapy and engineered cell therapies are also another promising approach. Peptide and small molecule activators have shown efficacy in early-stage preclinical studies. Finally, lifestyle modifications, such as fat-restricted diets, cessation of cigarette smoking, and a diet rich in antioxidants may potentially suppress lipoprotein abnormalities in FLD patients and help preserve LCAT activity and renal function but have not been adequately tested.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Preclinical and early-stage clinical trials demonstrate the promise of novel LCAT therapies as HDL-raising agents that may be used to treat not only FLD but potentially also atherosclerosis and other disorders with low or dysfunctional HDL.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mol.0000000000000673","type":"journal-article","created":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T12:10:34Z","timestamp":1582114234000},"page":"71-79","source":"Crossref","is-referenced-by-count":24,"title":["Novel lecithin:cholesterol acyltransferase-based therapeutic approaches"],"prefix":"10.1097","volume":"31","author":[{"given":"Lita A.","family":"Freeman","sequence":"first","affiliation":[{"name":"Lipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sotirios K.","family":"Karathanasis","sequence":"additional","affiliation":[{"name":"Lipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda"},{"name":"NeoProgen, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan T.","family":"Remaley","sequence":"additional","affiliation":[{"name":"Lipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230917","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1373\/clinchem.2016.257725","article-title":"The changing face of HDL and the best way to measure it","volume":"63","author":"Karathanasis","year":"2017","journal-title":"Clin Chem"},{"key":"R2-20230917","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jacl.2018.09.005","article-title":"JCL roundtable: high-density lipoprotein function and reverse cholesterol transport","volume":"12","author":"Cuchel","year":"2018","journal-title":"J Clin Lipidol"},{"key":"R3-20230917","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/B978-0-12-407867-3.00007-X","article-title":"Role of lecith: cholesterol acyltransferase in HDL metabolism and atherosclerosis","author":"Ahsan","year":"2014","journal-title":"The HDL handbook (second edition): biological functions and clinical implications"},{"key":"R4-20230917","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0006-3002(62)90156-7","article-title":"The mechanism of the plasma cholesterol esterification reaction: plasma fatty acid transferase","volume":"65","author":"Glomset","year":"1962","journal-title":"Biochim Biophys Acta"},{"key":"R5-20230917","article-title":"LCAT deficiency: update for 2020","author":"Calabresi","year":"2020","journal-title":"Curr Opin Lipidol"},{"key":"R6-20230917","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1038\/ncomms7250","article-title":"Structure and function of lysosomal phospholipase A2 and lecith: cholesterol acyltransferase","volume":"6","author":"Glukhova","year":"2015","journal-title":"Nat Commun"},{"key":"R7-20230917","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/j.jacc.2010.11.092","article-title":"Carriers of lecithin cholesterol acyltransferase gene mutations have accelerated atherogenesis as assessed by carotid 3.0-T magnetic resonance imaging [corrected]","volume":"58","author":"Duivenvoorden","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R8-20230917","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1016\/j.jacc.2010.11.091","article-title":"Low levels of high-density lipoprotein cholesterol due to lecithin:cholesterol acyltransferase mutations increase carotid atherosclerosis","volume":"58","author":"Fazio","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R9-20230917","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1161\/CIRCULATIONAHA.118.034706","article-title":"Complete and partial lecithin:cholesterol acyltransferase deficiency is differentially associated with atherosclerosis","volume":"138","author":"Oldoni","year":"2018","journal-title":"Circulation"},{"key":"R10-20230917","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1023\/A:1006865420286","article-title":"Uptake and metabolism of lipoprotein-X in mesangial cells","volume":"175","author":"Lynn","year":"1997","journal-title":"Mol Cell Biochem"},{"key":"R11-20230917","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1194\/jlr.D090233","article-title":"Plasma lipoprotein-X quantification on filipin-stained gels: monitoring recombinant LCAT treatment ex vivo","volume":"60","author":"Freeman","year":"2019","journal-title":"J Lipid Res"},{"key":"R12-20230917","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1023\/A:1006836704042","article-title":"Effect of lipoprotein-X on lipid metabolism in rat kidney","volume":"173","author":"Ly","year":"1997","journal-title":"Mol Cell Biochem"},{"key":"R13-20230917","doi-asserted-by":"crossref","first-page":"e0150083","DOI":"10.1371\/journal.pone.0150083","article-title":"Lipoprotein X causes renal disease in LCAT deficiency","volume":"11","author":"Ossoli","year":"2016","journal-title":"PLoS One"},{"key":"R14-20230917","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1124\/jpet.118.251876","article-title":"LCAT enzyme replacement therapy reduces LP-X and improves kidney function in a mouse model of familial LCAT deficiency","volume":"368","author":"Vaisman","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"R15-20230917","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.3390\/jcm8111860","article-title":"Lipid profile rather than the LCAT mutation explains renal disease in familial LCAT deficiency","volume":"8","author":"Lamiquiz-Moneo","year":"2019","journal-title":"J Clin Med"},{"key":"R16-20230917","first-page":"A14164","article-title":"Reduction in ApoB levels after a single dose of MEDI6012 in subjects receiving high-intensity statin therapy suggests enhancement of low-density lipoprotein receptor-mediated reverse cholesterol transport","volume":"136","author":"Abuhsira","year":"2017","journal-title":"Circulation"},{"key":"R17-20230917","first-page":"A14664","article-title":"Safety, pharmacokinetics, and pharmacodynamics of single ascending doses of recombinant human lecithin-cholesterol acyltransferase (MEDI6012) in subjects with stable coronary heart disease","volume":"136","author":"George","year":"2017","journal-title":"Circulation"},{"key":"R18-20230917","first-page":"49","article-title":"Multiple ascending doses of recombinant human lecithin-cholesterol acyltransferase in patients with atherosclerosis: phase 2a primary results","author":"Bonaca","year":"2018","journal-title":"Eur Heart J"},{"key":"R19-20230917","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCRESAHA.115.306223","article-title":"Safety and tolerability of ACP-501, a recombinant human lecithin:cholesterol acyltransferase, in a phase 1 single-dose escalation study","volume":"118","author":"Shamburek","year":"2016","journal-title":"Circ Res"},{"key":"R21-20230917","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1161\/ATVBAHA.118.311987","article-title":"Recombinant LCAT (lecithin:cholesterol acyltransferase) rescues defective HDL (high-density lipoprotein)-mediated endothelial protection in acute coronary syndrome","volume":"39","author":"Ossoli","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R22-20230917","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1124\/jpet.110.169540","article-title":"Effect of recombinant human lecithin cholesterol acyltransferase infusion on lipoprotein metabolism in mice","volume":"335","author":"Rousset","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"R23-20230917","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jacl.2015.12.007","article-title":"Familial lecithin:cholesterol acyltransferase deficiency: first-in-human treatment with enzyme replacement","volume":"10","author":"Shamburek","year":"2016","journal-title":"J Clin Lipidol"},{"key":"R24-20230917","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/MED.0000000000000466","article-title":"Controversy over the atherogenicity of lipoprotein-X","volume":"26","author":"Miida","year":"2019","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"R25-20230917","doi-asserted-by":"crossref","first-page":"e00554","DOI":"10.1002\/prp2.554","article-title":"LCAT protects against lipoprotein-X Formation in a murine model of drug-induced intrahepatic cholestasis","volume":"8","author":"Amar","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"R26-20230917","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jacl.2016.10.013","article-title":"Lipoprotein-X in cholestatic patients causes xanthomas and promotes foam cell formation in human macrophages","volume":"11","author":"Suzuki","year":"2017","journal-title":"J Clin Lipidol"},{"issue":"(5 Pt 1)","key":"R27-20230917","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/0016-5085(90)90356-6","article-title":"Hyperviscosity syndrome in a hypercholesterolemic patient with primary biliary cirrhosis","volume":"98","author":"Rosenson","year":"1990","journal-title":"Gastroenterology"},{"key":"R28-20230917","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1074\/jbc.M115.672790","article-title":"Agonistic human antibodies binding to lecithin-cholesterol acyltransferase modulate high density lipoprotein metabolism","volume":"291","author":"Gunawardane","year":"2016","journal-title":"J Biol Chem"},{"key":"R29-20230917","doi-asserted-by":"crossref","first-page":"D840","DOI":"10.1093\/nar\/gkw971","article-title":"The ExAC browser: displaying reference data information from over 60 000 exomes","volume":"45","author":"Karczewski","year":"2017","journal-title":"Nucleic Acids Research"},{"key":"R30-20230917","first-page":"S1175","article-title":"Lecithin cholesterol acyltransferase promotes reverse cholesterol transport and attenuates atherosclerosis progression in New Zealand white rabbits","volume":"120","author":"Zhou","year":"2009","journal-title":"Circulation, MA"},{"key":"R34-20230917","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan4672","article-title":"Gene therapy comes of age","volume":"359","author":"Dunbar","year":"2018","journal-title":"Science"},{"key":"R37-20230917","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.metabol.2008.11.019","article-title":"Adenoviral expression of human lecithin-cholesterol acyltransferase in nonhuman primates leads to an antiatherogenic lipoprotein phenotype by increasing high-density lipoprotein and lowering low-density lipoprotein","volume":"58","author":"Amar","year":"2009","journal-title":"Metabolism"},{"key":"R38-20230917","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/978-1-60327-369-5_13","article-title":"Adeno-associated viruses as liver-directed gene delivery vehicles: focus on lipoprotein metabolism","volume":"1027","author":"Lagor","year":"2013","journal-title":"Methods Mol Biol"},{"key":"R40-20230917","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.2040-1124.2011.00133.x","article-title":"Adipocytes as a vehicle for ex vivo gene therapy: novel replacement therapy for diabetes and other metabolic diseases","volume":"2","author":"Kuroda","year":"2011","journal-title":"J Diabetes Investig"},{"key":"R41-20230917","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3858\/emm.2011.43.3.021","article-title":"Fibrin glue increases the cell survival and the transduced gene product secretion of the ceiling culture-derived adipocytes transplanted in mice","volume":"43","author":"Aoyagi","year":"2011","journal-title":"Exp Mol Med"},{"key":"R42-20230917","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood.2019000040","article-title":"Resveratrol trimer enhances gene delivery to hematopoietic stem cells by reducing antiviral restriction at endosomes","volume":"134","author":"Ozog","year":"2019","journal-title":"Blood"},{"key":"R43-20230917","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1161\/01.ATV.10.1.95","article-title":"Use of synthetic peptide analogues to localize lecithin:cholesterol acyltransferase activating domain in apolipoprotein A-I","volume":"10","author":"Anantharamaiah","year":"1990","journal-title":"Arteriosclerosis"},{"key":"R44-20230917","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1021\/bi0481489","article-title":"Apolipoprotein E is the major physiological activator of lecithin-cholesterol acyltransferase (LCAT) on apolipoprotein B lipoproteins","volume":"44","author":"Zhao","year":"2005","journal-title":"Biochemistry"},{"key":"R45-20230917","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1194\/jlr.M800584-JLR200","article-title":"LCAT synthesized by primary astrocytes esterifies cholesterol on glia-derived lipoproteins","volume":"50","author":"Hirsch-Reinshagen","year":"2009","journal-title":"J Lipid Res"},{"key":"R46-20230917","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1042\/BJ20150832","article-title":"High-density lipoprotein mimetics: promises and challenges","volume":"472","author":"Sviridov","year":"2015","journal-title":"Biochem J"},{"key":"R47-20230917","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1073\/pnas.73.5.1422","article-title":"The solid phase synthesis of a protein activator for lecithin-cholesterol acyltransferase corresponding to human plasma apoC-I","volume":"73","author":"Sigler","year":"1976","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R48-20230917","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/00365517809104900","article-title":"Lecithin:cholesterol acyltransferase activation and lipid binding by synthetic fragments of apolipoprotein C-I","volume":"150","author":"Soutar","year":"1978","journal-title":"Scand J Clin Lab Invest Suppl"},{"key":"R49-20230917","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1073\/pnas.77.6.3154","article-title":"Activation of lecithin:cholesterol acyltransferase by a synthetic model lipid-associating peptide","volume":"77","author":"Pownall","year":"1980","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R50-20230917","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1016\/S0021-9258(20)79708-5","article-title":"The mechanism of activation of lecithin:cholesterol acyltransferase by apolipoprotein A-I and an amphiphilic peptide","volume":"255","author":"Yokoyama","year":"1980","journal-title":"J Biol Chem"},{"key":"R51-20230917","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/prot.340030307","article-title":"Lecithin:cholesterol acyltransferase activation by synthetic amphipathic peptides","volume":"3","author":"Subbarao","year":"1988","journal-title":"Proteins"},{"key":"R52-20230917","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1021\/bi00385a002","article-title":"pH-dependent bilayer destabilization by an amphipathic peptide","volume":"26","author":"Subbarao","year":"1987","journal-title":"Biochemistry"},{"key":"R53-20230917","doi-asserted-by":"crossref","first-page":"10256","DOI":"10.1016\/S0021-9258(17)39239-6","article-title":"Studies of synthetic peptide analogs of the amphipathic helix. Correlation of structure with function","volume":"260","author":"Chung","year":"1985","journal-title":"J Biol Chem"},{"key":"R54-20230917","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1016\/S0021-9258(18)83789-9","article-title":"Properties of lipid complexes with amphipathic helix-forming peptides. Role of distribution of peptide charges","volume":"264","author":"Epand","year":"1989","journal-title":"J Biol Chem"},{"key":"R56-20230917","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-319-17350-4_3","article-title":"Apolipoprotein mimetic peptides for stimulating cholesterol efflux","author":"Li","year":"2015","journal-title":"Apolipoprotein mimetics in the management of human disease"},{"key":"R57-20230917","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/978-1-60327-369-5_16","article-title":"Measurement of lecithin-cholesterol acyltransferase activity with the use of a Peptide-proteoliposome substrate","author":"Vaisman","year":"2013","journal-title":"Lipoproteins and Cardiovascular Disease: Methods and Protocols"},{"key":"R59-20230917","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.metabol.2011.08.006","article-title":"Small molecule activation of lecithin cholesterol acyltransferase modulates lipoprotein metabolism in mice and hamsters","volume":"61","author":"Chen","year":"2012","journal-title":"Metabolism"},{"key":"R60-20230917","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1124\/jpet.117.240457","article-title":"Lecithin\u200a:\u200acholesterol acyltransferase activation by sulfhydryl-reactive small molecules: role of cysteine-31","volume":"362","author":"Freeman","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"R62-20230917","doi-asserted-by":"crossref","first-page":"26139","DOI":"10.1074\/jbc.270.44.26139","article-title":"Chicken lecithin-cholesterol acyltransferase. Molecular characterization reveals unusual structure and expression pattern","volume":"270","author":"Hengstschlager-Ottnad","year":"1995","journal-title":"J Biol Chem"},{"key":"R63-20230917","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1432-1033.1989.tb14996.x","article-title":"Alterations in plasma lipoproteins and apolipoproteins associated with estrogen-induced hyperlipidemia in the laying hen","volume":"184","author":"Hermier","year":"1989","journal-title":"Eur J Biochem"},{"issue":"(Suppl_1)","key":"R64-20230917","first-page":"A15584","article-title":"A novel and orally available lecithin cholesterol acyltransferase activator prevents the progression of plaque accumulation in an atherosclerosis mouse model","volume":"136","author":"Yamada","year":"2017","journal-title":"Circulation"},{"key":"R69-20230917","doi-asserted-by":"crossref","first-page":"e41604","DOI":"10.7554\/eLife.41604","article-title":"Molecular basis for activation of lecithin:cholesterol acyltransferase by a compound that increases HDL cholesterol","volume":"7","author":"Manthei","year":"2018","journal-title":"elife"},{"key":"R70-20230917","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/00365517509108157","article-title":"Plasma lipoproteins in familial lecithin: cholesterol acyltransferase deficiency: effects of dietary manipulation","volume":"142","author":"Glomset","year":"1975","journal-title":"Scand J Clin Lab Invest Suppl"},{"key":"R71-20230917","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.atherosclerosis.2013.02.034","article-title":"Amelioration of circulating lipoprotein profile and proteinuria in a patient with LCAT deficiency due to a novel mutation (Cys74Tyr) in the lid region of LCAT under a fat-restricted diet and ARB treatment","volume":"228","author":"Naito","year":"2013","journal-title":"Atherosclerosis"},{"key":"R72-20230917","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.atherosclerosis.2008.11.033","article-title":"Changes in lipoprotein profile and urinary albumin excretion in familial LCAT deficiency with lipid lowering therapy","volume":"205","author":"Yee","year":"2009","journal-title":"Atherosclerosis"},{"key":"R73-20230917","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0014-4800(81)90004-6","article-title":"Cigarette smoke-induced depression in LCAT activity","volume":"35","author":"Mulligan","year":"1981","journal-title":"Exp Mol Pathol"},{"key":"R74-20230917","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1161\/01.ATV.14.2.248","article-title":"Modification of LCAT activity and HDL structure. New links between cigarette smoke and coronary heart disease risk","volume":"14","author":"McCall","year":"1994","journal-title":"Arterioscler Thromb"},{"key":"R75-20230917","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/jbt.2570100302","article-title":"Inhibition of lecithin: cholesterol acyltransferase activity in human blood plasma by cigarette smoke extract and reactive aldehydes","volume":"10","author":"Chen","year":"1995","journal-title":"J Biochem Toxicol"},{"key":"R76-20230917","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0005-2760(95)00092-Q","article-title":"Gas-phase cigarette smoke inhibits plasma lecithin-cholesterol acyltransferase activity by modification of the enzyme's free thiols","volume":"1258","author":"Bielicki","year":"1995","journal-title":"Biochim Biophys Acta"},{"key":"R77-20230917","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/BF02536999","article-title":"Effect of peroxyl radicals on lecithin\/cholesterol acyltransferase activity in human plasma","volume":"30","author":"Chen","year":"1995","journal-title":"Lipids"},{"key":"R78-20230917","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1177\/1535370216657447","article-title":"Featured article: alterations of lecithin cholesterol acyltransferase activity and apolipoprotein A-I functionality in human sickle blood","volume":"241","author":"Soupene","year":"2016","journal-title":"Exp Biol Med"},{"key":"R79-20230917","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/jid.2013.359","article-title":"Antipsoriatic therapy recovers high-density lipoprotein composition and function","volume":"134","author":"Holzer","year":"2014","journal-title":"J Invest Dermatol"},{"key":"R80-20230917","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/jid.2013.447","article-title":"High-density lipoprotein cholesterol function improves after successful treatment of psoriasis: a step forward in the right direction","volume":"134","author":"Mehta","year":"2014","journal-title":"J Invest Dermatol"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000000673","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T08:05:14Z","timestamp":1694937914000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000000673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0000000000000673","relation":{},"ISSN":["0957-9672","1473-6535"],"issn-type":[{"value":"0957-9672","type":"print"},{"value":"1473-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}